<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073229</url>
  </required_header>
  <id_info>
    <org_study_id>5R01AI032391-15</org_study_id>
    <secondary_id>5R01AI032391-11</secondary_id>
    <secondary_id>5R01AI032391-14</secondary_id>
    <nct_id>NCT00073229</nct_id>
  </id_info>
  <brief_title>Immune Function of Infants With HIV</brief_title>
  <official_title>Killer Cells and Viral Load in Vertical HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will evaluate data from infants born to HIV infected mothers in
      order to better characterize disease progression in early HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of HIV-specific cytotoxic T-lymphocytes (CTL) in controlling viremia and protecting
      against disease progression following vertical infection may be dependent upon CTL functional
      responses as well as on the timing of detection, magnitude, and breadth of the responses.
      Novel and sensitive assay systems (MHC-peptide tetramers, ELISPOT assays, intracellular
      cytokine assays) have enhanced the detection and characterization of virus-specific CTL
      responses in the peripheral blood. This study will use these novel methods to examine the
      timing of detection, magnitude, specificity, and in vitro functional properties of
      HIV-specific CTL in infants; to evaluate the effects of potent combination antiretroviral
      therapy on HIV-specific CTL in infants; and to evaluate the immunogenicity of recombinant
      pox-based vaccines in HIV infected infants with prolonged viral suppression following early
      potent combination antiretroviral therapy.

      Blood samples from infants born to HIV infected women will be obtained from infants enrolled
      in other HIV trials. Generally, samples will be obtained at birth, Week 1, and Months 1, 2,
      4, 6, 9, and 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants and children born to HIV infected women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Luzuriaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gibson L, Piccinini G, Lilleri D, Revello MG, Wang Z, Markel S, Diamond DJ, Luzuriaga K. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol. 2004 Feb 15;172(4):2256-64.</citation>
    <PMID>14764694</PMID>
  </reference>
  <reference>
    <citation>Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL; PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004 Jun 10;350(24):2471-80.</citation>
    <PMID>15190139</PMID>
  </reference>
  <reference>
    <citation>Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis. 2004 Aug;4(8):510-8. Review.</citation>
    <PMID>15288824</PMID>
  </reference>
  <reference>
    <citation>Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, Van Rompay K, Marthas M, Haigwood N, Mascola JR, Luzuriaga K, Jones SA, Mathieson BJ, Newell ML; Ghent IAS Working Group on HIV in Women Children. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):169-77. Review.</citation>
    <PMID>14722451</PMID>
  </reference>
  <reference>
    <citation>Scott ZA, Beaumier CM, Sharkey M, Stevenson M, Luzuriaga K. HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol. 2003 Jun 1;170(11):5786-92.</citation>
    <PMID>12759463</PMID>
  </reference>
  <results_reference>
    <citation>Sanchez-Merino V, Nie S, Luzuriaga K. HIV-1-specific CD8+ T cell responses and viral evolution in women and infants. J Immunol. 2005 Nov 15;175(10):6976-86.</citation>
    <PMID>16272358</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2003</study_first_submitted>
  <study_first_submitted_qc>November 18, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2003</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Katherine Luzuriaga, MD</name_title>
    <organization>University of Massachusetts</organization>
  </responsible_party>
  <keyword>AIDS</keyword>
  <keyword>Vertical Transmission</keyword>
  <keyword>Acute Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

